Body
Revision 25-3; Effective Sept. 1, 2025
Grantees must submit the following reports accurately and timely throughout the grant term, regardless of status, to report on progress and implementation.
3410 Financial Status Report (FSR)
Revision 26-1; Effective Jan. 8, 2026
The FSR includes all expenditures, program income and non-HHSC funding for the defining three months in each quarter with amounts received from HHSC. The FSR is due within 30 calendar days after the end of each quarter. Final FSR is due 45 calendar days after the end of the grant term.
3420 Monthly Voucher Packet
Revision 26-1; Effective Jan. 8, 2026
The monthly voucher packet is submitted to request reimbursement for the cost reimbursement portion of the grant. The monthly voucher packet and supporting documentation is due the last business day of the month following the month where expenses were incurred or services provided. Final voucher is due 45 days after the end of the grant term.
3430 Match Report
Revision 26-1; Effective Jan. 8, 2026
Matching funds refer to non-federal resources such as money and in-kind contributions. The Centers for Disease Control and Prevention (CDC) requires the BCCS program to provide $1 in match for every $3 of CDC funding awarded. Grantees must secure, budget, expend and report the non-federal match. Grantees submit match reports and the completed form by email to HHSC FCS Finance 30 days after the end of each quarter.
3440 Clinical Performance Measures
Revision 26-1; Effective Jan. 8, 2026
Performance Indicators and Reports
Grantees are required to meet National Breast and Cervical Cancer Early Detection Program (NBCCEDP) performance measures. The following performance indicators (PIs) are used to assess, in part, the grantee’s effectiveness providing BCCS services. Screening indicators are as follows:
| PI No. | Service | Description |
|---|---|---|
| 1 | Cervical | Percentage of initial program pap tests provided to women 30 and older who have never or rarely been screened (Goal: >=35%) |
| 2 | Cervical | Percentage of pap test records with planned and completed diagnostic follow-up (Goal: >= 90%) |
| 3 | Cervical | Percentage of pap test records where time between screening and final diagnosis was <= 60 days (Goal: >= 75%) |
| 4 | Cervical | Percentage of pap test records with a diagnosis of HSIL, CIN2, CIN3/CIS or invasive cervical carcinoma where treatment has been started (Goal: >=90) |
| 5 | Cervical | Percentage of pap test records with a diagnosis of HSIL, CIN2 or CIN3/CIS where time between diagnosis and treatment is <= 60 days (Goal: >= 80%) |
| 6 | Breast | Percentage of mammogram screening records with abnormal results and completed diagnostic follow-up (Goal: >= 90%) |
| 7 | Breast | Percentage of mammogram screening records with completed follow-up and time between screening and final diagnosis was <= 60 days (Goal: >= 75%) |
| 8 | Breast | Percentage of breast cancer records with a diagnosis of CIS, other, DCIS, or invasive breast cancer that have treatment started (Goal: >= 90%) |
| 9 | Breast | Percentage of breast cancer records with a diagnosis of CIS, other, DCIS, or invasive breast cancer where time between diagnosis and treatment is <= 60 days (Goal: >= 80%) |
- A minimum of 35% of all NBCCEDP-reimbursed cervical cancer screenings should be provided to program-eligible women 30 and older who have never been screened or not screened within the last 10 years through the program. Grantees may use conventional or liquid-based cytology.
Cervical cancer diagnostic indicators are:
- A minimum of 90% of cervical screening records with planned and complete diagnostic follow-up.
- The interval between screening and final diagnosis of cervical cancer screenings should be 60 days or less for a minimum of 75% of the women.
- A minimum of 90% of cervical cancer records with final diagnosis of HSIL, CIN2, CIN 3, CIS or invasive cervical cancer must have started treatment.
- The interval between final diagnosis and initiation of treatment for HSIL, CIN2, CIN3, CIS or invasive cervical cancer should be 60 days or less for a minimum of 80% of the women.
Breast cancer diagnostic indicators are:
- A minimum of 90% of mammogram screening records with abnormal results must have a completed diagnostic follow-up.
- The interval between completed follow-up and time between abnormal screening and final diagnosis should be 60 days or less for a minimum of 75% of women.
- A minimum of 90% of breast cancer records with a final diagnosis of CIS, other, or DCIS, or invasive breast cancer must have started treatment.
- The interval between final diagnosis and initiation of treatment for breast cancer records with a final diagnosis of CIS, other, or DCIS, or invasive breast cancer should be 60 days or less for a minimum of 80% of women.
Note: These performance measures are subject to change. Performance Indicator Report (PIR) is due no later than the 10th day of the end of the quarter to Med-ITHelpDesk@hhs.texas.gov.
Follow-up Report (FUR)
FUR summarizes all pending follow-up examinations, diagnosis, and treatment initiation for the specified time frame. The FUR is due by email no later than the 10th day of the end of the month to HHSC Med_IT Helpdesk.
Minimum Data Elements (MDE)
MDE are a set of standardized data elements used to collect demographic and clinical information on women screened with BCCS funds. MDEs are due no later than the 10th calendar day of the end of the month to HHSC Med_IT Helpdesk. Grantees must submit the questionnaire linked in the MDE Calendar and Instructions to HHSC by the due date. Once HHSC receives the completed questionnaire, the deliverable is met.